<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00187720</url>
  </required_header>
  <id_info>
    <org_study_id>787</org_study_id>
    <nct_id>NCT00187720</nct_id>
  </id_info>
  <brief_title>Genetic Basis for Variation in the Renal Elimination of Metformin</brief_title>
  <official_title>Genetic Basis for Variation in the Renal Elimination of Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is part of a large multi-investigator grant to look at the pharmacogenetics
      of a number of membrane transporters. We will study individuals with particular genotypes of
      the human organic cation transporter, (hOCT2), to test the hypothesis that genetic variation
      in hOCT2 is associated with variation in the renal clearance of the antidiabetic agent,
      metformin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug, which is used in the treatment of Type II diabetes, has a narrow therapeutic range.
      Its net renal clearance by secretion (i.e., renal clearance minus filtration clearance)
      ranges from approximately 100 ml/min to 800ml/min in normal, healthy subjects. Although many
      factors may contribute to inter-individual variation in renal secretory clearance, initial
      estimates of heritability (greater than 0.6) suggest that genetic factors play an important
      role in the renal secretion of metformin. Available evidence supports the idea that hOCT2 is
      the primary transporter involved in the first-step of renal secretion of metformin, i.e.,
      uptake from the blood to the tubule cell across the basolateral membrane. In particular, (a)
      hOCT2 is the primary organic cation transporter on the basolateral membrane of the human
      kidney; and (b) metformin interacts with and is translocated by hOCT2 in heterologous
      expression systems.

      In recent studies, we identified four variants (M165I, A270S, R400C, and K432Q) with
      ethnic-specific allele frequencies ≥1% [6] that have altered function in studies in
      heterologous expression systems. In addition, we identified a common haplotype of hOCT2 and
      one haplotype that contain the non-synonymous cSNP, A270S. We will determine whether
      variability in the renal secretory clearance of the model organic cation, metformin, in
      healthy individuals is associated with genetic variation in hOCT2. In particular, we will
      determine whether the renal clearance of metformin differs in individuals who are homozygous
      for the common haplotype of OCT2 (OCT2*1) and those who are heterozygous for the less common
      haplotype OCT2*3D, which we have identified in a comprehensive screen of ethnically
      identified DNA samples. We will also determine whether individuals who are heterozygous for
      the less common OCT2 variants, M165I, R400C and K432Q, have reduced renal clearances of
      metformin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Clearance of Metformin</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours</time_frame>
    <description>To test whether individuals with genetic variants of the human organic cation transporter, OCT2, exhibit altered renal elimination of metformin we will measure the difference in renal clearance between reference and variant groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Other Conditions That May Be A Focus of Clinical Attention</condition>
  <arm_group>
    <arm_group_label>OCT2-variant Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with OCT2-variant genotype will be given a single oral dose of 850 mg of metformin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OCT2-reference Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with OCT2-reference genotype will be given a single oral dose of 850 mg of metformin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Subjects will be given a single oral dose of 850 mg of metformin</description>
    <arm_group_label>OCT2-variant Group</arm_group_label>
    <arm_group_label>OCT2-reference Group</arm_group_label>
    <other_name>GLUCOPHAGE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects have previously participated in the Study Of Pharmacogenetics In Ethnically
             Diverse Populations (SOPHIE) study.

          -  18-40 years old

          -  Possess a pre-specified genotype for OCT2

        Exclusion Criteria:

          -  Taking any regular medications other than vitamins.

          -  Individuals with anemia (hemoglobin &lt; 12 g/dL), an elevation in liver enzymes to
             higher than double the respective normal value, or elevated creatinine concentrations
             (males ≥ 1.5 mg/dL, females ≥ 1.4 mg/dL)

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Giacomini, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francsico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, Choi JH, Huang Y, Brett CM, Burchard EG, Giacomini KM. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics. 2009 Jul;19(7):497-504. doi: 10.1097/FPC.0b013e32832cc7e9.</citation>
    <PMID>19483665</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>March 31, 2011</results_first_submitted>
  <results_first_submitted_qc>December 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 10, 2013</results_first_posted>
  <last_update_submitted>December 6, 2012</last_update_submitted>
  <last_update_submitted_qc>December 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Control</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment were 5/2003 through 4/10/2007. Location was General Clinical Research Center (GCRC) at San Francisco General Hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Organic Cation Transporter 2 (OCT2)-Variant Group</title>
          <description>Subjects with OCT2-variant genotype will be given a single oral dose of 850 mg of metformin</description>
        </group>
        <group group_id="P2">
          <title>Organic Cation Transporter 2 (OCT2)-Reference Group</title>
          <description>Subjects with OCT2-reference genotype will be given a single oral dose of 850 mg of metformin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OCT2-reference Group</title>
          <description>Subjects with OCT2-reference genotype will be given a single oral dose of 850 mg of metformin</description>
        </group>
        <group group_id="B2">
          <title>OCT2-variant Group</title>
          <description>Subjects with OCT2-variant genotype will be given a single oral dose of 850 mg of metformin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.3" spread="6.6"/>
                    <measurement group_id="B2" value="31.2" spread="5.5"/>
                    <measurement group_id="B3" value="28.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance of Metformin</title>
        <description>To test whether individuals with genetic variants of the human organic cation transporter, OCT2, exhibit altered renal elimination of metformin we will measure the difference in renal clearance between reference and variant groups.</description>
        <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours</time_frame>
        <population>Analysis was per protocol. The sample size of 23 subjects will enable us to detect a significant difference (at the p &lt; 0.05 level; α = 0.05, β = 0.80) in the renal clearance of metformin between individuals who are homozygous for the reference OCT2 and those who carry the OCT2 variant A270S allele.</population>
        <group_list>
          <group group_id="O1">
            <title>OCT2-variant Group</title>
            <description>The renal clearance of metformin in subjects heterozygous for the variant OCT2 genotype (808G/T, *3D) following a single oral dose of 850 mg of metformin.</description>
          </group>
          <group group_id="O2">
            <title>OCT2-reference Group</title>
            <description>The renal clearance of metformin in subjects homozygous for the reference OCT2 genotype (808G/G) following a single oral dose of 850 mg of metformin.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance of Metformin</title>
          <description>To test whether individuals with genetic variants of the human organic cation transporter, OCT2, exhibit altered renal elimination of metformin we will measure the difference in renal clearance between reference and variant groups.</description>
          <population>Analysis was per protocol. The sample size of 23 subjects will enable us to detect a significant difference (at the p &lt; 0.05 level; α = 0.05, β = 0.80) in the renal clearance of metformin between individuals who are homozygous for the reference OCT2 and those who carry the OCT2 variant A270S allele.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="614" spread="158"/>
                    <measurement group_id="O2" value="441" spread="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>OCT2-reference Group</title>
          <description>Subjects with OCT2-reference genotype will be given a single oral dose of 850 mg of metformin</description>
        </group>
        <group group_id="E2">
          <title>OCT2-variant Group</title>
          <description>Subjects with OCT2-variant genotype will be given a single oral dose of 850 mg of metformin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Recruitment of subjects with interested genotypes was our limitation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kathy Giacomini, Ph.D</name_or_title>
      <organization>UCSF</organization>
      <phone>4154761936</phone>
      <email>Kathy.Giacomini@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

